Back From the Dead: What Dog Cloning Means for Our Human Future
By Osagie K. Obasogie,
Alternet
| 06. 16. 2008
Good Morning America recently televised a world exclusive that caught many pet owners' attention: Dog cloning is now commercially available for people who want to bring their dead and dying companions back to life. Brought to you by BioArts International, a Northern California biotech startup, man and his dead best friend can now be, as the company's marketing slogan states, "Best Friends Again." And again. And again.
But it'll cost you. Rather than taking orders, BioArts will auction off five dog cloning slots in mid-June. Bids start at $100,000.
Despite Good Morning America's numerous awards for excellence in televised journalism, its coverage of this story was not its finest moment. A number of omissions and oversights led the segment to present dog cloning as a largely unproblematic way to deal with the grief of our pets' inevitable deaths. But several untold stories behind this story need to be put front and center.
The ABC morning show presented BioArts' CEO Lou Hawthorne as the next in a long line of pioneering Californian bio executives. But rather than being a new venture...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...
